GEN talked with several contract development and manufacturing organizations (CDMOs) and/or contract research organizations (CROs) about new ways they are addressing AAV manufacturing challenges.

Innovative delivery techniques, including high-tech nanoparticles and electroporationdevices, may convey more gene therapies into the clinic.